{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:56:18Z","timestamp":1791608178632,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Diabetic macular ischaemia (DMI) is a complication of diabetic retinopathy that leads to irreversible vision loss. DMI is characterised by reduced retinal vessel density and enlargement of the foveal avascular zone (FAZ). Despite its clinical burden, there is no formal consensus on the definition of DMI, and no approved treatment. Semaphorin 3A (Sema3A) is an axonal guidance molecule that blocks revascularisation of the ischaemic retina. Sema3A modulation is therefore a promising mechanism of action for the treatment of ischaemic eye diseases. BI 764524 is an intravitreal anti-Sema3A ischaemia modulator agent.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>HORNBILL (NCT04424290) is a phase I\/IIa trial comprising a non-randomised, open-label, single rising dose (SRD) part and a randomised, masked, sham-controlled multiple dose (MD) part to investigate the safety, tolerability and early biological response of ischaemia modulator BI 764524 in adults (\u226518 years) with DMI. DMI will be defined using optical coherence tomography angiography (OCTA) as either any degree of disruption in the retinal vascularity (SRD) or a FAZ of \u22650.5 mm<jats:sup>2<\/jats:sup> (MD). Subjects in the SRD part will receive 0.5, 1.0 or 2.5 mg of BI 764524; the maximum tolerated dose will then be used in the MD part. A minimum of 12 subjects will be enrolled into the SRD part; planned enrollment is 30 for the MD part. The primary endpoint of the SRD part is the number of subjects with dose-limiting adverse events (AEs) until day 8. The primary endpoint of the MD part is the number of subjects with drug-related AEs from baseline to end of study, and secondary endpoints include change from baseline in the size of the FAZ, best-corrected visual acuity and central retinal thickness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>DMI is a poorly defined condition with no treatment options. HORNBILL is the first clinical trial to assess a treatment for DMI and to use OCTA as a means to define and examine DMI. The OCTA data generated in this trial could form the basis of formal diagnostic criteria for DMI. Furthermore, the novel mechanism of action (Sema3A modulation) explored in this trial has the potential to revolutionise the treatment landscape for patients with DMI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04424290\">NCT04424290<\/jats:ext-link>; EudraCT 2019-004432-28. Registered on 9 June 2020<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06527-y","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T13:03:33Z","timestamp":1660741413000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["HORNBILL: a phase I\/IIa trial examining the safety, tolerability and early response of BI 764524 in patients with diabetic retinopathy and diabetic macular ischaemia\u2014rationale, study design and protocol"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7693-522X","authenticated-orcid":false,"given":"Victor","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Sepah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"issue":"3","key":"6527_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4239\/wjd.v6.i3.489","volume":"6","author":"MM Nentwich","year":"2015","unstructured":"Nentwich MM, Ulbig MW. Diabetic retinopathy - ocular complications of diabetes mellitus. World J Diabetes. 2015;6(3):489\u201399.","journal-title":"World J Diabetes"},{"issue":"9","key":"6527_CR2","first-page":"2653","volume":"26","author":"TA Ciulla","year":"2003","unstructured":"Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema. Pathophysiol Screening Novel Ther. 2003;26(9):2653\u201364.","journal-title":"Pathophysiol Screening Novel Ther"},{"key":"6527_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17.","journal-title":"Eye Vis (Lond)"},{"issue":"suppl 1","key":"6527_CR4","doi-asserted-by":"publisher","first-page":"s84","DOI":"10.2337\/diacare.27.2007.S84","volume":"27","author":"DS Fong","year":"2004","unstructured":"Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. Retinopathy in diabetes. Diabetes Care. 2004;27(suppl 1):s84\u2013s7.","journal-title":"Diabetes Care"},{"issue":"9735","key":"6527_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"N Cheung","year":"2010","unstructured":"Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124\u201336.","journal-title":"Lancet"},{"issue":"1-2","key":"6527_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1900\/RDS.2015.12.159","volume":"12","author":"AJ Jenkins","year":"2015","unstructured":"Jenkins AJ, Joglekar MV, Hardikar AA, Keech AC, O'Neal DN, Januszewski AS. Biomarkers in diabetic retinopathy. Rev Diabet Stud. 2015;12(1-2):159\u201395.","journal-title":"Rev Diabet Stud"},{"issue":"7","key":"6527_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00592-020-01506-8","volume":"57","author":"P Lanzetta","year":"2020","unstructured":"Lanzetta P, Sarao V, Scanlon PH, Barratt J, Porta M, Bandello F, et al. Fundamental principles of an effective diabetic retinopathy screening program. Acta Diabetol. 2020;57(7):785\u201398.","journal-title":"Acta Diabetol"},{"key":"6527_CR8","doi-asserted-by":"crossref","unstructured":"Rubsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018;19(4):942.","DOI":"10.3390\/ijms19040942"},{"issue":"3","key":"6527_CR9","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1167\/iovs.12-11103","volume":"54","author":"DA Sim","year":"2013","unstructured":"Sim DA, Keane PA, Zarranz-Ventura J, Fung S, Powner MB, Platteau E, et al. The effects of macular ischemia on visual acuity in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2013;54(3):2353\u201360.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"6527_CR10","first-page":"e3064","volume":"10","author":"M Usman","year":"2018","unstructured":"Usman M. An overview of our current understanding of diabetic macular ischemia (DMI). Cureus. 2018;10(7):e3064.","journal-title":"Cureus."},{"issue":"1","key":"6527_CR11","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1111\/aos.12519","volume":"93","author":"G Liew","year":"2015","unstructured":"Liew G, Sim DA, Keane PA, Tan AG, Mitchell P, Wang JJ, et al. Diabetic macular ischaemia is associated with narrower retinal arterioles in patients with type 2 diabetes. Acta Ophthalmol. 2015;93(1):e45\u201351.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"6527_CR12","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1167\/iovs.15-18034","volume":"57","author":"PD Bradley","year":"2016","unstructured":"Bradley PD, Sim DA, Keane PA, Cardoso J, Agrawal R, Tufail A, et al. The evaluation of diabetic macular ischemia using optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2016;57(2):626\u201331.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6527_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40942-017-0062-2","volume":"3","author":"JMB de Barros Garcia","year":"2017","unstructured":"de Barros Garcia JMB, Isaac DLC, Avila M. Diabetic retinopathy and OCT angiography: clinical findings and future perspectives. Int J Retina Vitreous. 2017;3:14.","journal-title":"Int J Retina Vitreous"},{"key":"6527_CR14","doi-asserted-by":"publisher","first-page":"7589841","DOI":"10.1155\/2019\/7589841","volume":"2019","author":"F Scarinci","year":"2019","unstructured":"Scarinci F, Varano M, Parravano M. Retinal sensitivity loss correlates with deep capillary plexus impairment in diabetic macular ischemia. J Ophthalmol. 2019;2019:7589841.","journal-title":"J Ophthalmol"},{"key":"6527_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/OPTH.S235892","volume":"14","author":"M Abdelshafy","year":"2020","unstructured":"Abdelshafy M, Abdelshafy A. Functional and structural changes of the retinal nerve fiber layer and ganglion cell complex in heavy smokers. Clin Ophthalmol. 2020;14:397\u2013404.","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"6527_CR16","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1007\/s10792-018-1034-8","volume":"39","author":"D Gildea","year":"2019","unstructured":"Gildea D. The diagnostic value of optical coherence tomography angiography in diabetic retinopathy: a systematic review. Int Ophthalmol. 2019;39(10):2413\u201333.","journal-title":"Int Ophthalmol"},{"issue":"11","key":"6527_CR17","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1016\/j.ophtha.2016.07.008","volume":"123","author":"C Balaratnasingam","year":"2016","unstructured":"Balaratnasingam C, Inoue M, Ahn S, McCann J, Dhrami-Gavazi E, Yannuzzi LA, et al. Visual acuity is correlated with the area of the foveal avascular zone in diabetic retinopathy and retinal vein occlusion. Ophthalmology. 2016;123(11):2352\u201367.","journal-title":"Ophthalmology."},{"key":"6527_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.preteyeres.2013.01.005","volume":"35","author":"JM Provis","year":"2013","unstructured":"Provis JM, Dubis AM, Maddess T, Carroll J. Adaptation of the central retina for high acuity vision: cones, the fovea and the avascular zone. Prog Retin Eye Res. 2013;35:63\u201381.","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"6527_CR19","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ajo.2013.05.033","volume":"156","author":"DA Sim","year":"2013","unstructured":"Sim DA, Keane PA, Zarranz-Ventura J, Bunce CV, Fruttiger M, Patel PJ, et al. Predictive factors for the progression of diabetic macular ischemia. Am J Ophthalmol. 2013;156(4):684\u201392.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"6527_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40662-019-0160-3","volume":"6","author":"KY Tey","year":"2019","unstructured":"Tey KY, Teo K, Tan ACS, Devarajan K, Tan B, Tan J, et al. Optical coherence tomography angiography in diabetic retinopathy: a review of current applications. Eye Vision. 2019;6(1):37.","journal-title":"Eye Vision"},{"issue":"2","key":"6527_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4103\/JOCO.JOCO_83_20","volume":"32","author":"F Bazvand","year":"2020","unstructured":"Bazvand F, Ghassemi F. Artifacts in macular optical coherence tomography. J Curr Ophthalmol. 2020;32(2):123\u201331.","journal-title":"J Curr Ophthalmol"},{"key":"6527_CR22","doi-asserted-by":"crossref","unstructured":"Cheung G, Pearce E, Fenner B, Sen P, Chong V, Sivaprasad S. Looking ahead: visual and anatomical endpoints in future trials of diabetic macular ischemia. Ophthalmologica. 2021;244(5):451-64.","DOI":"10.1159\/000515406"},{"key":"6527_CR23","doi-asserted-by":"crossref","unstructured":"Iragavarapu-Charyulu V, Wojcikiewicz E, Urdaneta A. Semaphorins in angiogenesis and autoimmune diseases: therapeutic targets? Front Immunol. 2020;11(346).","DOI":"10.3389\/fimmu.2020.00346"},{"issue":"24","key":"6527_CR24","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1242\/dev.011452","volume":"134","author":"F Moret","year":"2007","unstructured":"Moret F, Renaudot C, Bozon M, Castellani V. Semaphorin and neuropilin co-expression in motoneurons sets axon sensitivity to environmental semaphorin sources during motor axon pathfinding. Development. 2007;134(24):4491\u2013501.","journal-title":"Development."},{"issue":"5","key":"6527_CR25","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/j.jcjd.2012.07.380","volume":"36","author":"A Cerani","year":"2012","unstructured":"Cerani A, Tetreault N, Binet F, Rezende F, Sitaras N, Lapalme E, et al. The guidance protein Semaphorin3A provokes vascular leakage in diabetic retinopathy. Can J Diabetes. 2012;36(5):S52.","journal-title":"Can J Diabetes"},{"issue":"22","key":"6527_CR26","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1182\/blood-2010-10-311589","volume":"117","author":"JS Joyal","year":"2011","unstructured":"Joyal JS, Sitaras N, Binet F, Rivera JC, Stahl A, Zaniolo K, et al. Ischemic neurons prevent vascular regeneration of neural tissue by secreting semaphorin 3A. Blood. 2011;117(22):6024\u201335.","journal-title":"Blood."},{"key":"6527_CR27","doi-asserted-by":"crossref","unstructured":"Zippel N, Kenny C, Wu H, Garneau M, Kroe-Barrett R, Gupta P, et al. Sema3A antibody BI-X prevents cell permeability and cytoskeletal collapse in HRMECs and increases tip cell density in mouse oxygen-induced retinopathy. Trans Vis Sci Tech.\u00a02022;11(6):17.","DOI":"10.1167\/tvst.11.6.17"},{"issue":"10","key":"6527_CR28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9","volume":"17","author":"J Babb","year":"1998","unstructured":"Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med. 1998;17(10):1103\u201320.","journal-title":"Stat Med"},{"issue":"13","key":"6527_CR29","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/sim.3230","volume":"27","author":"B Neuenschwander","year":"2008","unstructured":"Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med. 2008;27(13):2420\u201339.","journal-title":"Stat Med"},{"issue":"2","key":"6527_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ophtha.2016.10.008","volume":"124","author":"WA Samara","year":"2017","unstructured":"Samara WA, Shahlaee A, Adam MK, Khan MA, Chiang A, Maguire JI, et al. Quantification of diabetic macular ischemia using optical coherence tomography angiography and its relationship with visual acuity. Ophthalmology. 2017;124(2):235\u201344.","journal-title":"Ophthalmology."},{"issue":"14","key":"6527_CR31","first-page":"1689","volume":"52","author":"AR Glassman","year":"2011","unstructured":"Glassman AR, Network DRCR. Evaluation of masking success of sham ocular injections. Invest Ophthalmol Vis Sci. 2011;52(14):1689.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"6527_CR32","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/ije\/dyu115","volume":"43","author":"A Hr\u00f3bjartsson","year":"2014","unstructured":"Hr\u00f3bjartsson A, Emanuelsson F, Skou Thomsen AS, Hilden J, Brorson S. Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. Int J Epidemiol. 2014;43(4):1272\u201383.","journal-title":"Int J Epidemiol"},{"key":"6527_CR33","first-page":"1397","volume":"19","author":"W Yu","year":"2013","unstructured":"Yu W, Bai Y, Han N, Wang F, Zhao M, Huang L, et al. Inhibition of pathological retinal neovascularization by semaphorin 3A. Mol Vis. 2013;19:1397\u2013405.","journal-title":"Mol Vis"},{"key":"6527_CR34","doi-asserted-by":"crossref","unstructured":"Nakamura S, Nishinaka A, Hidaka Y, Shimazawa M, Thomas L, Bakker RA, et al. Efficacy of an anti-Semaphorin 3A neutralizing antibody in an experimental retinal vein occlusion mouse model. Invest Ophthalmol Vis Sci. 2022;63(8):14.","DOI":"10.1167\/iovs.63.8.14"},{"issue":"2","key":"6527_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/bjophthalmol-2011-301087","volume":"96","author":"K Manousaridis","year":"2012","unstructured":"Manousaridis K, Talks J. Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease? Br J Ophthalmol. 2012;96(2):179\u201384.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"6527_CR36","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41433-019-0606-9","volume":"34","author":"J DaCosta","year":"2020","unstructured":"DaCosta J, Bhatia D, Talks J. The use of optical coherence tomography angiography and optical coherence tomography to predict visual acuity in diabetic retinopathy. Eye. 2020;34(5):942\u20137.","journal-title":"Eye."},{"issue":"3","key":"6527_CR37","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s10792-020-01633-9","volume":"41","author":"H Okumichi","year":"2021","unstructured":"Okumichi H, Itakura K, Yuasa Y, Fukuto A, Kiuchi Y. Foveal structure in nanophthalmos and visual acuity. Int Ophthalmol. 2021;41(3):805\u201313.","journal-title":"Int Ophthalmol"},{"issue":"7","key":"6527_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1167\/tvst.9.7.10","volume":"9","author":"M Ashraf","year":"2020","unstructured":"Ashraf M, Sampani K, Abu-Qamar O, Cavallerano J, Silva PS, Aiello LP, et al. Optical coherence tomography angiography projection artifact removal: impact on capillary density and interaction with diabetic retinopathy severity. Transl Vision Sci Technol. 2020;9(7):10.","journal-title":"Transl Vision Sci Technol"},{"issue":"9","key":"6527_CR39","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.ophtha.2008.03.009","volume":"115","author":"JS Sunness","year":"2008","unstructured":"Sunness JS, Rubin GS, Broman A, Applegate CA, Bressler NM, Hawkins BS. Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. Ophthalmology. 2008;115(9):1480\u20138, 8.e1-2.","journal-title":"Ophthalmology"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06527-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06527-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06527-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T13:09:24Z","timestamp":1660741764000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06527-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6527"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06527-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"assertion":[{"value":"14 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Receipt of signed and dated informed consent is a requirement for inclusion in the trial. A trial investigator or delegate will obtain informed, freely given, written consent from each subject via a consent form, after confirming that the subject understands the content of the form. This trial will be initiated only after all required legal documentation has been reviewed and approved by the responsible IRB\/IEC and CA according to national and international regulations. The same applies for the implementation of changes introduced by amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate\u00a0{24}"}},{"value":"All authors consent to the publication of this article. The Boehringer Ingelheim transparency and publication policy can be found on the following web page: . The consent documents are available from the corresponding author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication\u00a0{32}"}},{"value":"VC declares that he is an employee of Janssen R&D LLC, but that this work was performed prior to Janssen employment and is not endorsed by Janssen; at the time of project initiation, he was an employee of Boehringer Ingelheim. QDN declares funding from Boehringer Ingelheim, Genentech, Gilead, Regeneron and Santen and consulting for AsclepiX, Bayer, Regeneron and Santen. YS declares financial support from Boehringer Ingelheim. AG and EP declare that they are employees of Boehringer Ingelheim.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests\u00a0{28}"}}],"article-number":"669"}}